Blackstone Life Sciences Overview
- Investor Type
- PE/Buyout
- Status
- Active
- Investments
- 114
- Portfolio
- 20
- Exits
- 61
Blackstone Life Sciences General Information
Description
Blackstone Life Sciences is a segment of the private equity firm, The Blackstone Group. The firm prefers to invest in companies operating in the life science, pharma, medical device research, biotechnology, and healthcare sectors. The firm is a result of The Blackstone Group's acquisition of Clarus Ventures in 2018.
Contact Information
Website
Formerly Known As
Clarus Ventures, LLC, Clarus, Clarus-Ventures, Klarus Ventures, ClarusVentures, Clarus Venture, Clarus Ventures, Limited Liability Company, Clarus Ventures
Year Founded
2005
Investor Status
Actively Seeking New Investments
Trade Association
National Venture Capital Association (NVCA)
Primary Investor Type
PE/Buyout
Other Investor Types
Venture Capital
Primary Office
- 101 Main Street
- Suite 1210
- Cambridge, MA 02142
- United States
+1 (617) 000-0000
Blackstone Life Sciences Investments & Acquisitions (114)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Company Stage | Lead Partner |
|---|---|---|---|---|---|---|
| 00000 00000000000 | 19-Nov-2020 | 00000 00000 | 0000 | Drug Discovery | Clinical Trials - Phase 3 | |
| 0000000 0000000000 | 30-Sep-2020 | 00000 00000 | 00000 | Drug Delivery | Clinical Trials - Phase 3 | 00000 0000000 00 |
| 0000000 0000000000 | 17-Aug-2020 | 0000000000 | 000 | Buildings and Property | 00000000 000000000 00.0 | |
| 000000 | 28-Jul-2020 | 00000 00000 | 00000 | Drug Discovery | Clinical Trials - Phase 2 | 000 00000000 00 |
| Annexon Biosciences | 30-Jun-2020 | Later Stage VC | 00000 | Drug Discovery | Clinical Trials - Phase 1 | 000000 0000000000 00.0 |
Blackstone Life Sciences Exits (61)
| Company Name | Exit Date | Exit Type | Exit Size |
|---|---|---|---|
| 000000 | 16-Oct-2020 | 000 | 00000 |
| 0000000 000000 | 25-Sep-2020 | 000 | 0000 |
| 0000000 0000000000 | 24-Jul-2020 | 000 | 00000 |
| 000000 00000000000 | 07-Nov-2019 | 000 | 0000 |
| Essa Pharma | 23-Aug-2019 | Public Investment 2nd Offering | 0000 |
Blackstone Life Sciences Fund Performance
| Fund Name | Vintage | Size | Dry Powder | DPI | RVPI | TVPI | IRR |
|---|
This information is available in the PitchBook Platform. To explore Blackstone Life Sciences‘s full profile, request access.
Request a free trialBlackstone Life Sciences Investments by Industry, Year, and Region
Investments by Industry
Investments by Year
Investments by Region
PitchBook’s data visualizations quickly surface an investor’s historical investments—showing a breakdown of activity by industry, year and region.
Request a free trialBlackstone Life Sciences Team (34)
| Name | Title | Deals | Funds | Boards | Office |
|---|---|---|---|---|---|
| Kurt Wheeler | Co-Founder & Managing Director | 00 | 0 | 0 | Cambridge, MA |
| Nicholas Simon | Managing Director | 0 | 0 | 0 | Cambridge, MA |
| Robert Liptak | Managing Director | 0 | 0 | Cambridge, MA | |
| Kiran Reddy MD | Venture Partner | 0 | 0 | Cambridge, MA | |
| Scott Requadt JD | Venture Partner | 0 | 0 | 0 | Cambridge, MA |